Telecomunicazioni
Growing at an Annualized Rate of 12%, the HPAPI and Cytotoxic Drugs Contract Manufacturing Market is Projected to Reach USD 25 Billion by 2030, Claims Roots Analysis
The market is currently dominated by the presence of mid-sized and large companies, which represent 75% of the industry stakeholders. Further, more than 65% of CMOs claim to have the capabilities to manufacture HPAPIs and cytotoxic drugs across all scales of operation (preclinical, clinical and commercial).
More than 205 manufacturing facilities have been established by various players, worldwide; of these, 48% are in Europe , followed by those based in North America (35%). Other prominent regions, serving as bases of operations for such companies, include ( ) China , India and Australia .
More than 100 agreements have been inked in the last 6 years; majority of which were acquisitions. Other popular types of partnership models adopted by players engaged in this domain include R&D agreements (11%), manufacturing agreements (11%) and technology licensing deals (9%).
More than 55% of such initiatives were focused on expanding manufacturing facilities, followed those by those undertaken for building new facilities (24%). It is worth mentioning that most of expansion initiatives (90%) were carried out in Europe and North America .
Whereas, rest (15%) of the capacity is being used for preclinical / clinical scale manufacturing of HPAPIs. In addition, over 50% of the total current global, installed HPAPI manufacturing capacity is installed in
Europe .
In addition, the market in the Asia Pacific is projected to grow at a relatively faster rate (~13%). Further, the majority share (85%) of contract service revenues is anticipated to be generated from commercial scale operations; this trend is unlikely to change in the foreseen future.
The USD 25 billion (by 2030) financial opportunity within the HPAPI and cytotoxic drugs contract manufacturing market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom the manufacturing of HPAPIs and cytotoxic drugs is largely being outsourced owing to the exorbitant costs associated with setting-up of in-house expertise. The report includes detailed transcripts of discussions held with the following experts:
The research covers profiles of key players that offer manufacturing services for HPAPIs and cytotoxic drugs, featuring a company overview, information on their respective service portfolios, manufacturing facilities and capabilities, recent developments and an informed future outlook.
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
Gaurav Chaudhary
+1(415) 800-3415
+44(122)391-1091
Gaurav.Chaudhary@rootsanalysis.com
Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg